Delta-Fly Pharma, Inc. (TYO:4598)

Delta-Fly Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	-	-	-	300	300
Revenue Growth (YoY)	-	-	-	-	200.00%
Gross Profit	-	-	-	300	300
Selling, General & Admin	271	229	261	287	253
Research & Development	1,437	1,118	1,011	940	866
Other Operating Expenses	-	56	43	34	33
Operating Expenses	1,708	1,403	1,315	1,261	1,152
Operating Income	-1,708	-1,403	-1,315	-961	-852
Currency Exchange Gain (Loss)	-1	-5	-5	-	-3
Other Non Operating Income (Expenses)	-10	-19	-5	-3	-4
Pretax Income	-1,719	-1,427	-1,325	-964	-859
Income Tax Expense	2	2	3	3	3
Net Income	-1,721	-1,429	-1,328	-967	-862
Net Income to Common	-1,721	-1,429	-1,328	-967	-862
Shares Outstanding (Basic)	9	7	6	5	5
Shares Outstanding (Diluted)	9	7	6	5	5
Shares Change (YoY)	22.38%	26.91%	4.61%	17.64%	3.08%
EPS (Basic)	-195.56	-198.72	-234.37	-178.52	-187.22
EPS (Diluted)	-195.56	-198.72	-234.37	-178.52	-187.22
Free Cash Flow	-1,834	-1,280	-1,303	-940	-726
Free Cash Flow Per Share	-208.41	-178.00	-229.96	-173.54	-157.68
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-320.33%	-284.00%
Profit Margin	-	-	-	-322.33%	-287.33%
Free Cash Flow Margin	-	-	-	-313.33%	-242.00%
EBITDA	-1,707	-1,402	-1,314	-960	-850
EBITDA Margin	-	-	-	-	-283.33%
D&A For EBITDA	1	1	1	1	2
EBIT	-1,708	-1,403	-1,315	-961	-852
EBIT Margin	-	-	-	-	-284.00%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.